Go Pro
→ Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AlloVir, Inc. stock logo
ALVR
AlloVir
$3.88
-1.5%		$4.24
$7.96
▼
$24.15
$19.57M0.6315,685 shs56,523 shs
Celularity, Inc. stock logo
CELU
Celularity
$0.70
+0.1%		$0.72
$0.56
▼
$4.31
$20.13M0.5441,043 shs11,415 shs
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
$2.68
-8.2%		$4.71
$1.50
▼
$44.10
$4.67M2.3272,278 shs130,111 shs
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.14
+2.7%		$1.32
$0.81
▼
$2.46
$18.51M1.546,149 shs45,559 shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AlloVir, Inc. stock logo
ALVR
AlloVir
-0.76%-5.97%-10.86%-24.52%+58.23%
Celularity, Inc. stock logo
CELU
Celularity
+0.77%+1.80%-7.91%-13.98%-80.47%
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
-7.01%-14.37%-35.11%-60.11%-89.16%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-4.31%-0.89%-22.92%-21.83%-13.95%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AlloVir, Inc. stock logo
ALVR
AlloVir
$3.88
-1.5%		$4.24
$7.96
▼
$24.15
$19.57M0.6315,685 shs56,523 shs
Celularity, Inc. stock logo
CELU
Celularity
$0.70
+0.1%		$0.72
$0.56
▼
$4.31
$20.13M0.5441,043 shs11,415 shs
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
$2.68
-8.2%		$4.71
$1.50
▼
$44.10
$4.67M2.3272,278 shs130,111 shs
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.14
+2.7%		$1.32
$0.81
▼
$2.46
$18.51M1.546,149 shs45,559 shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AlloVir, Inc. stock logo
ALVR
AlloVir
-0.76%-5.97%-10.86%-24.52%+58.23%
Celularity, Inc. stock logo
CELU
Celularity
+0.77%+1.80%-7.91%-13.98%-80.47%
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
-7.01%-14.37%-35.11%-60.11%-89.16%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-4.31%-0.89%-22.92%-21.83%-13.95%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00
N/AN/AN/A
Celularity, Inc. stock logo
CELU
Celularity
2.00
Hold$6.00762.32% Upside
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
2.00
Hold$30.001,019.40% Upside
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
2.25
Hold$10.00777.19% Upside

Current Analyst Ratings Breakdown

Latest HCWB, ALVR, CELU, and MRKR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/6/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/5/2026
Celularity, Inc. stock logo
CELU
Celularity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/17/2026
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/6/2026
Celularity, Inc. stock logo
CELU
Celularity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/24/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
5/28/2026
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$12.00 ➝ $30.00
5/20/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/A$29.35 per shareN/A
Celularity, Inc. stock logo
CELU
Celularity
$26.55M0.76N/AN/A($1.32) per share-0.53
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
$50K85.76N/AN/A$5.06 per share0.53
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/AN/AN/AN/A$1.01 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AlloVir, Inc. stock logo
ALVR
AlloVir
-$190.42M-$20.23N/AN/AN/AN/A-71.03%-61.27%N/A
Celularity, Inc. stock logo
CELU
Celularity
-$91.72M-$3.33N/AN/AN/A-345.45%N/A-77.94%N/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
-$7.96M-$56.75N/AN/AN/A-34.73%-486.87%-29.19%N/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$12.16M-$0.61N/AN/AN/A-343.03%-73.29%-59.70%N/A

Latest HCWB, ALVR, CELU, and MRKR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
-$1.98-$11.58-$9.60-$11.58$5.73 million$0.14 million
8/14/2026Q2 2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$0.25-$0.09+$0.16-$0.09$0.68 millionN/A
5/15/2026Q1 2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$0.18-$0.16+$0.02-$0.16$0.78 million$0.75 million
5/14/2026Q1 2026
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
-$2.64$0.37+$3.01$2.22$6.54 million$6.54 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/A
Celularity, Inc. stock logo
CELU
Celularity
N/AN/AN/AN/AN/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
N/AN/AN/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AlloVir, Inc. stock logo
ALVR
AlloVir
N/A
86.78
86.78
Celularity, Inc. stock logo
CELU
Celularity
N/A
0.15
0.15
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
N/A
0.09
0.09
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/A
4.79
4.79

Institutional Ownership

CompanyInstitutional Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
66.05%
Celularity, Inc. stock logo
CELU
Celularity
19.02%
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
2.96%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
22.39%

Insider Ownership

CompanyInsider Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
32.07%
Celularity, Inc. stock logo
CELU
Celularity
17.30%
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
9.10%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
5.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
AlloVir, Inc. stock logo
ALVR
AlloVir
1105.04 million3.43 millionNo Data
Celularity, Inc. stock logo
CELU
Celularity
22028.95 million23.94 millionOptionable
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
401.60 million1.45 millionNot Optionable
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
6016.67 million15.72 millionNot Optionable

Recent News About These Companies

Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
June 26, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2943342/zacks-industry-outlook-indivior-aurinia-ironwood-altimmune-and-marker?cid=cs-stocknewsapi-ft-press_releases-2943342
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
June 25, 2026  |  zacks.comhttps://www.zacks.com/commentary/2942605/5-small-drug-stocks-to-invest-in-amid-a-biotech-comeback?cid=cs-stocknewsapi-ft-industry_outlook-2942605
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?
May 20, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2924277/marker-therapeutics-mrkr-upgraded-to-buy-what-does-it-mean-for-the-stock?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2924277
Marker Therapeutics Sets Date for 2026 Annual Meeting
May 19, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MRKR-Q/pressreleases/141978/marker-therapeutics-sets-date-for-2026-annual-meeting/
Marker Therapeutics (MRKR) price target decreased by 12.83% to 8.02
April 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/marker-therapeutics-mrkr-price-target-decreased-by-12-83-to-8-02/ar-AA20ulsd
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates
March 18, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2886298/marker-therapeutics-inc-mrkr-reports-q4-loss-tops-revenue-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2886298
Marker Therapeutics Reports Encouraging Phase 1 APOLLO Data and Corporate Developments in Immuno-Oncology
March 18, 2026  |  quiverquant.comQ
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
March 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/18/3258655/0/en/marker-therapeutics-reports-year-end-2025-corporate-and-financial-results.html
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/18/3240173/0/en/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference.html
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology
January 26, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/good-morning-america-features-baylor-college-of-medicine-pancreatic-cancer-study-utilizing-marker-therapeutics-mar-t-cell-technology-1035745259
Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Pasithea Therapeutics Corp (KTTA) and TransMedics Group (TMDX)
January 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/37179524/analysts-offer-insights-on-healthcare-companies-marker-therapeutics-mrkr-pasithea-therapeutics-corp-ktta-and-transmedics-group-tmdx/
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
January 21, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2820215/mrkr-stock-up-nearly-114-in-3-months-here-s-what-you-need-to-know?cid=cs-stocknewsapi-ft-analyst_blog|price_surge_/_plunge-2820215
Marker Therapeutics, Inc. Common Stock (MRKR)
January 9, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/mrkr/insider-activity
MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?
January 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2813452/marker-therapeutics-inc-mrkr-now-trades-above-golden-cross-time-to-buy?cid=cs-stocknewsapi-ft-tale_of_the_tape|golden_crossover-2813452
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
January 7, 2026  |  zacks.comhttps://www.zacks.com/commentary/2813120/5-small-drug-stocks-to-buy-as-industry-recovery-picks-up?cid=cs-stocknewsapi-ft-industry_outlook-2813120
Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer
January 5, 2026  |  msn.comhttps://www.msn.com/en-us/science/biochemistry/marker-therapeutics-announces-publication-on-mar-t-cells-in-pancreatic-cancer/ar-AA1TC4mx
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
January 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/05/3212598/0/en/baylor-college-of-medicine-publishes-promising-safety-and-efficacy-results-of-multi-antigen-targeted-t-cells-in-patients-with-pancreatic-cancer.html
Here's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash Wisely
December 18, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/heres-why-marker-therapeutics-nasdaq-112909067.html
HC Wainwright & Co. initiates coverage of Marker Therapeutics (MRKR) with buy recommendation
December 8, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/hc-wainwright-co-initiates-coverage-of-marker-therapeutics-mrkr-with-buy-recommendation/ar-AA1RXI9t
Marker Therapeutics initiated with a buy at HC Wainwright
December 8, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/marker-therapeutics-initiated-with-a-buy-at-hc-wainwright/ar-AA1RX2XB

New MarketBeat Followers Over Time

Media Sentiment Over Time

AlloVir stock logo

AlloVir NASDAQ:ALVR

$3.88 -0.06 (-1.52%)
As of 08/13/2026

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Celularity stock logo

Celularity NASDAQ:CELU

$0.70 +0.00 (+0.07%)
Closing price 04:00 PM Eastern
Extended Trading
$0.70 +0.00 (+0.32%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

HCW Biologics stock logo

HCW Biologics NASDAQ:HCWB

$2.68 -0.24 (-8.22%)
Closing price 04:00 PM Eastern
Extended Trading
$2.74 +0.05 (+2.05%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Marker Therapeutics stock logo

Marker Therapeutics NASDAQ:MRKR

$1.14 +0.03 (+2.70%)
Closing price 04:00 PM Eastern
Extended Trading
$1.14 0.00 (-0.09%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas